Advertisement
ABT vs SYK
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- ABT and SYK both operate in the medical devices segment of healthcare, with ABT offering broader exposure across diagnostics, nutrition, and established pharmaceuticals alongside devices.
- Recent weeks saw ABT trading near $102 amid a $385 million DOJ settlement resolution and multiple FDA device approvals, while SYK hovered around $275 with ongoing supply challenges in peripheral vascular and new Foot & Ankle product launches.
- ABT reported strong Q2 comparable sales growth of 4.8% and raised full-year adjusted EPS guidance, whereas SYK delivered 9.0% organic sales growth in Q2 while narrowing full-year guidance following cyber incident recovery.
- Market sentiment for ABT reflects dividend continuity (411 consecutive quarters) offset by litigation closure, while SYK faces scrutiny from a securities investigation alongside innovation momentum in robotics and planning software.
- Relative positioning shows ABT with larger scale (market cap ~$178 billion) versus SYK (~$106 billion), with both exhibiting beta below 1.0 indicating lower volatility than the broader market.
Introduction
Investors and traders evaluating healthcare exposure often compare ABT and SYK due to their overlapping focus on medical technologies and devices. This analysis examines recent performance, business models, and market positioning to highlight contrasts relevant to those seeking diversified or sector-specific opportunities. The comparison draws on observable data from the past several weeks to inform relative assessments without forward projections.
ABT Overview and Recent Performance
Abbott Laboratories develops and manufactures a diversified portfolio including medical devices, diagnostics, nutrition products, and established pharmaceuticals. In recent market activity, shares traded near $102.61 following a Department of Justice settlement of $385 million related to a prior infant formula recall, which resolved outstanding claims without admission of liability. The company also declared its 411th consecutive quarterly dividend of $0.63 per share. Product developments included FDA authorizations for advanced cardiac ablation systems and pulsed field ablation technology. These factors contributed to sentiment amid broader sector dynamics, with the stock reflecting both litigation resolution and ongoing innovation in diabetes monitoring and structural heart areas.
SYK Overview and Recent Performance
Stryker Corporation specializes in medical technologies with emphasis on orthopedics, surgical equipment, neurotechnology, and spine products. Recent market activity placed shares near $275.12 as the company showcased Foot & Ankle innovations, including surgical planning software and smart fixation systems at industry conferences. Supply disruptions in peripheral vascular segments persisted alongside a planned acquisition of ZuriMED Technologies. Q2 results highlighted recovery from an earlier cyber incident with 9.0% organic sales growth, though a securities investigation announcement added pressure. These elements shaped performance in a period of operational focus and product expansion.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots page that features select AI trading bots optimized for prevailing market conditions. While hundreds of bots trade thousands of tickers across varied styles, strategies, timeframes, and performance metrics, only those demonstrating suitability for current environments appear in this section. Available bots span ranges of historical win rates, drawdown profiles, and trade frequencies, allowing users to review detailed statistics before consideration. The platform provides transparent data on each bot’s approach and ticker coverage. Review the Trending AI Robots page for additional details.
Head-to-Head Comparison
ABT maintains broader diversification across diagnostics and nutrition compared with SYK’s concentrated focus on surgical and orthopedic technologies. Growth drivers for ABT include recent device approvals and diabetes care expansions, while SYK emphasizes robotics platforms and procedural planning tools. Recent momentum reflects ABT navigating litigation closure alongside SYK addressing supply issues and investigation developments. Risk factors differ with ABT carrying exposure to regulatory and recall-related matters, whereas SYK contends with operational disruptions and legal scrutiny. Sector exposure remains aligned in healthcare devices, yet ABT’s larger scale provides different liquidity and dividend characteristics relative to SYK’s higher operating margins in core segments. Market sentiment incorporates both firms’ innovation pipelines tempered by company-specific headlines.
Tickeron AI Verdict
Based on observable factors including trend consistency in recent weeks, stability of dividend history for ABT, and relative positioning amid catalysts such as product approvals versus supply challenges for SYK, Tickeron’s AI models currently assign a modestly higher probabilistic preference to ABT for scenarios emphasizing continuity and diversified exposure. This assessment remains probabilistic and subject to evolving market data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Hold and SYK is a Buy.
ABT | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 65 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 92 | |
SMR RATING 1..100 | 68 | 52 | |
PRICE GROWTH RATING 1..100 | 58 | 64 | |
P/E GROWTH RATING 1..100 | 7 | 86 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABT's Valuation (4) in the Medical Specialties industry is in the same range as SYK (7). This means that ABT’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (92) in the Medical Specialties industry is in the same range as ABT (100). This means that SYK’s stock grew similarly to ABT’s over the last 12 months.
SYK's SMR Rating (52) in the Medical Specialties industry is in the same range as ABT (68). This means that SYK’s stock grew similarly to ABT’s over the last 12 months.
ABT's Price Growth Rating (58) in the Medical Specialties industry is in the same range as SYK (64). This means that ABT’s stock grew similarly to SYK’s over the last 12 months.
ABT's P/E Growth Rating (7) in the Medical Specialties industry is significantly better than the same rating for SYK (86). This means that ABT’s stock grew significantly faster than SYK’s over the last 12 months.
| ABT | SYK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 44% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 55% | N/A |
| MACD ODDS (%) | 4 days ago 59% | 2 days ago 70% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 53% |
| Advances ODDS (%) | 10 days ago 57% | 3 days ago 57% |
| Declines ODDS (%) | 2 days ago 55% | 8 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 41% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 57% | 2 days ago 49% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 2 FA rating(s) are green while SYK’s FA Score has 1 green FA rating(s).
- ABT’s FA Score: 2 green, 3 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
- ABT’s TA Score: 5 bullish, 6 bearish.
- SYK’s TA Score: 5 bullish, 4 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а -4.50% price change this week, while SYK (@Medical/Nursing Services) price change was +1.05% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.00%. For the same industry, the average monthly price growth was -5.06%, and the average quarterly price growth was -2.61%.
Reported Earning Dates
ABT is expected to report earnings on Oct 21, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.00% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
ABT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABT has been loosely correlated with MDT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ABT jumps, then MDT could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.